Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That. In the News Feb 17 Written by Christine Mackenzie Christine Mackenzie Previous Previous Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye Next Next Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That. In the News Feb 17 Written by Christine Mackenzie Christine Mackenzie
